Corporate green goals driving PAT adoption

GlaxoSmithKline plant managers are jumping on the process analytical technology train. But process control is not the sole driver. GSK, like other drugmakers, is seeing PAT provide a boost for its sustainability efforts.

The trend is currently most apparent in its pilot plants, according to PharmaManufacturing.com. Managers trying to reduce cycle times and realize energy and cost savings are considering and adopting the technology.

In a recent survey conducted by the online magazine, ten percent of respondents say that sustainability has become a key driver of their PAT efforts. About half of the 50 respondents say they see PAT as a means toward sustainability and green practices.

PAT has "moved up in status, and moved upstream in the development cycle," according to the article. "Manufacturers are beginning to equate PAT with reducing the environmental impact of processes."

- here's the article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.